Published in PLoS Med on April 04, 2006
Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers (Girasol) | NCT00925288
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis (2007) 2.93
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Degree distributions in sexual networks: a framework for evaluating evidence. Sex Transm Dis (2008) 2.15
Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61
Human papillomavirus and HPV vaccines: a review. Bull World Health Organ (2007) 1.55
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer (2007) 1.45
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis (2009) 1.35
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck (2010) 1.16
Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer (2011) 1.16
Is human papillomavirus vaccination likely to be a useful strategy in India? South Asian J Cancer (2013) 1.14
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine (2012) 1.08
Sexual behaviour and risk factors for the acquisition of human papillomavirus infections in young people in Italy: suggestions for future vaccination policies. BMC Public Health (2012) 1.01
Cancer incidence and survival among adolescents and young adults in Korea. PLoS One (2014) 1.01
An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol (2014) 0.99
Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ (2007) 0.98
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2007) 0.96
Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol (2008) 0.94
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health (2009) 0.94
Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection. Int J Nanomedicine (2012) 0.92
Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types. J Infect Dis (2012) 0.91
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol (2011) 0.89
Review of Gardasil. J Vaccines Vaccin (2010) 0.89
Lessons learned from successful Papanicolaou cytology cervical cancer prevention in the Socialist Republic of Vietnam. Diagn Cytopathol (2011) 0.87
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int J Infect Dis (2013) 0.86
Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study. BMJ Open (2012) 0.84
Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach. PLoS One (2012) 0.83
When do sexual partnerships need to be accounted for in transmission models of human papillomavirus? Int J Environ Res Public Health (2010) 0.83
Factors related to HPV vaccine uptake and 3-dose completion among women in a low vaccination region of the USA: an observational study. BMC Womens Health (2016) 0.82
Type-specific human papillomavirus biological features: validated model-based estimates. PLoS One (2013) 0.82
Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol (2011) 0.81
Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One (2013) 0.81
Prophylactic HPV vaccines. J Clin Pathol (2007) 0.80
Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial. Med Decis Making (2013) 0.79
Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies. PLoS One (2012) 0.78
Could the human papillomavirus vaccines drive virulence evolution? Proc Biol Sci (2015) 0.78
Impact of Heterogeneity in Sexual Behavior on Effectiveness in Reducing HIV Transmission with Test-and-Treat Strategy. PLoS Comput Biol (2016) 0.77
Mathematical model of HPV provides insight into impacts of risk factors and vaccine. PLoS Med (2006) 0.77
The impact of HPV female immunization in Italy: model based predictions. PLoS One (2014) 0.76
Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis (2009) 0.76
Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior. Emerg Infect Dis (2016) 0.75
Infection transmission and chronic disease models in the study of infection-associated cancers. Br J Cancer (2013) 0.75
Surveillance of human papilloma virus using reference laboratory data for the purpose of evaluating vaccine impact. Online J Public Health Inform (2014) 0.75
The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model. PLoS One (2015) 0.75
Knowledge, attitudes and practices regarding human papillomavirus vaccination among young women attending a tertiary institution in Singapore. Singapore Med J (2016) 0.75
Examining Provincial HPV Vaccination Schemes in Canada: Should We Standardise the Grade of Vaccination or the Number of Doses? Int Sch Res Notices (2015) 0.75
The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models. BMC Infect Dis (2013) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer (2003) 8.01
The cervical cancer epidemic that screening has prevented in the UK. Lancet (2004) 7.72
Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet (1987) 6.91
Measuring sexual behaviour: methodological challenges in survey research. Sex Transm Infect (2001) 6.21
Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst (2000) 5.32
Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med (2000) 4.73
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr (2003) 2.87
Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ (2001) 2.56
The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology (2002) 2.49
Evaluating human papillomavirus vaccination programs. Emerg Infect Dis (2004) 2.47
Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis (1995) 2.21
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis (2003) 2.06
Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol (2000) 2.00
Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis (2002) 1.99
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res (2001) 1.89
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 1.89
Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer (1999) 1.56
Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis (2005) 1.51
Modeling age- and time-specific incidence from seroprevalence:toxoplasmosis. Am J Epidemiol (1993) 1.50
The serological response to papillomaviruses. Semin Cancer Biol (1999) 1.50
An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect (2002) 1.40
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis (1996) 1.36
Determining transition probabilities: confusion and suggestions. Med Decis Making (1994) 1.35
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol (2003) 1.20
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol (1999) 1.16
Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol (2000) 1.14
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer (2000) 1.12
Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol (2004) 1.08
Advances in the diagnosis and treatment of human papillomavirus infections. Clin Obstet Gynecol (1999) 0.92
A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer (2002) 0.87
Contemporary theories of cervical carcinogenesis: the virus, the host, and the stem cell. Mod Pathol (2000) 0.83
Effect of a mass screening program on the risk of cervical cancer. Cancer Detect Prev (1991) 0.80
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet (2002) 5.21
Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. AIDS (2003) 4.87
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS (2010) 4.05
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One (2008) 3.32
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science (2006) 2.76
Scale-free networks and sexually transmitted diseases: a description of observed patterns of sexual contacts in Britain and Zimbabwe. Sex Transm Dis (2004) 2.75
Creating and validating an algorithm to measure AIDS mortality in the adult population using verbal autopsy. PLoS Med (2006) 2.70
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Modelling the impact of migration on the HIV epidemic in South Africa. AIDS (2007) 2.63
Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med (2006) 2.52
The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology (2002) 2.49
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Seroepidemiology of the human polyomaviruses. J Gen Virol (2003) 2.32
Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ (2006) 2.20
Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic? Lancet (2004) 2.20
Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm. AIDS (2011) 2.10
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics (2009) 2.05
Prevalences of sexually transmitted infections in young adults and female sex workers in Peru: a national population-based survey. Lancet Infect Dis (2012) 2.03
Back to basics in HIV prevention: focus on exposure. BMJ (2003) 1.99
Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst (2007) 1.87
The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione. Nutr Cancer (2010) 1.86
Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet (2012) 1.80
The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol (2005) 1.76
Cerebral palsy is characterized by protein mediators in cord serum. Ann Neurol (2004) 1.73
Vicious and virtuous circles in the dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example. J Infect Dis (2005) 1.71
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health (2007) 1.63
Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One (2009) 1.62
Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol (2008) 1.62
Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. J Adolesc Health (2007) 1.60
Clandestine induced abortion: prevalence, incidence and risk factors among women in a Latin American country. CMAJ (2009) 1.55
HIV incidence in 3 years of follow-up of a Zimbabwe cohort--1998-2000 to 2001-03: contributions of proximate and underlying determinants to transmission. Int J Epidemiol (2008) 1.54
Age at first sex and HIV infection in rural Zimbabwe. Stud Fam Plann (2007) 1.53
Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol (2007) 1.51
Prevalence and fate of type 1 diabetes-associated autoantibodies in cord blood samples from newborn infants of non-diabetic mothers. Diabetes Metab Res Rev (2002) 1.47
Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine (2009) 1.45
A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer (2002) 1.43
Assessing adult mortality in HIV-1-afflicted Zimbabwe (1998 -2003). Bull World Health Organ (2006) 1.42
Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease. J Infect Dis (2012) 1.39
The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med (2012) 1.35
The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling. PLoS Med (2008) 1.32
Individual level injection history: a lack of association with HIV incidence in rural Zimbabwe. PLoS Med (2005) 1.28
Appropriate evaluation of HIV prevention interventions: from experiment to full-scale implementation. Sex Transm Infect (2007) 1.26
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol (2003) 1.20
Who is getting Pap smears in urban Peru? Int J Epidemiol (2008) 1.19
Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care (2006) 1.16
Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol (2005) 1.15
Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health (2009) 1.15
Introducing human papillomavirus vaccines - questions remain. Ann Med (2008) 1.14
High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer (2004) 1.12
Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population--a candidate gene approach. Int J Cancer (2009) 1.11
Hair loss, insulin resistance, and heredity in middle-aged women. A population-based study. J Cardiovasc Risk (2003) 1.10
Three factor eating questionnaire-R18 as a measure of cognitive restraint, uncontrolled eating and emotional eating in a sample of young Finnish females. Int J Behav Nutr Phys Act (2009) 1.09
Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol (2003) 1.09
Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer (2011) 1.08
Maternal antibodies in breast milk protect the child from enterovirus infections. Pediatrics (2007) 1.07
Common polymorphisms (single-nucleotide polymorphisms SNP+45 and SNP+276) of the adiponectin gene regulate serum adiponectin concentrations and blood pressure in young Finnish men. Mol Genet Metab (2005) 1.05
Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. Int J Cancer (2012) 1.04
Determinants of maternal sex steroids during the first half of pregnancy. Obstet Gynecol (2011) 1.01
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer (2012) 1.01
Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer (2011) 1.00
Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer (2010) 1.00
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis (2013) 1.00
Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PLoS One (2012) 1.00
Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev (2005) 0.99
Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand J Infect Dis (2008) 0.98
Reaching the unreachable: providing STI control services to female sex workers via mobile team outreach. PLoS One (2013) 0.97
Is HIV out of control in the UK? An example of analysing patterns of HIV spreading using incidence-to-prevalence ratios. AIDS (2006) 0.97
Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer (2006) 0.96
Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. Eur J Cancer (2010) 0.95
Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners. Sex Transm Infect (2010) 0.95
Maternal herpesvirus infections and risk of acute lymphoblastic leukemia in the offspring. Am J Epidemiol (2003) 0.95
Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis (2010) 0.94
Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.93
Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. Am J Obstet Gynecol (2003) 0.93
Effect of long-term storage on hormone measurements in samples from pregnant women: the experience of the Finnish Maternity Cohort. Acta Oncol (2007) 0.93
HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions. Epidemics (2010) 0.93
Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.92
The role of sexually transmitted infections in male circumcision effectiveness against HIV--insights from clinical trial simulation. Emerg Themes Epidemiol (2006) 0.90